Ironwood医药(IRWD)2026年第一季度业绩表现亮眼,其核心产品Linzess在美国市场的净销售额实现同比97%的显著增长。尽管取得如此强劲的开局,该公司仍决定维持此前发布的2026年全年财务业绩指引,显示出管理层对年度目标的审慎信心。
Ironwood医药(IRWD)2026年第一季度业绩表现亮眼,其核心产品Linzess在美国市场的净销售额实现同比97%的显著增长。尽管取得如此强劲的开局,该公司仍决定维持此前发布的2026年全年财务业绩指引,显示出管理层对年度目标的审慎信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.